HIND Stock Rallies 70% Pre-Market Today Find Out Why

2025-09-17 10:13:03

(MENAFN- AsiaNet News)

Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrop has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied by over 60% in pre-market trading on Wednesday.

Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome.

In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company stated.

Get updates to this developing story <directly on Stocktwits.

MENAFN17092025007385015968ID1110074798

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.